[
  {
    "ts": null,
    "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=21d45bd51b4407dcf119349b0cd4084fbbe5320bfb9cdb2cf09fd28b76cb267e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765204805,
      "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
      "id": 137732365,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=21d45bd51b4407dcf119349b0cd4084fbbe5320bfb9cdb2cf09fd28b76cb267e"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Dec 8, 2025",
    "summary": "Companies in The News Are: WBD, NFLX, MRK, VSCO, NRG",
    "url": "https://finnhub.io/api/news?id=b490a087837ec366f5a346e9a7f92b7ac872f4f1829b11e7c38eef25e2ce4cd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765204020,
      "headline": "Company News for Dec 8, 2025",
      "id": 137732366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Companies in The News Are: WBD, NFLX, MRK, VSCO, NRG",
      "url": "https://finnhub.io/api/news?id=b490a087837ec366f5a346e9a7f92b7ac872f4f1829b11e7c38eef25e2ce4cd1"
    }
  },
  {
    "ts": null,
    "headline": "Watch 5 Bigwigs in December After Double-Digit Returns Past Month",
    "summary": "Five market giants, CVNA, WMT, AMAT, FCX and MRK, delivered double-digit returns last month with more room to run in December.",
    "url": "https://finnhub.io/api/news?id=69a17417fb192bb42074c8db2788f230a77150ffe46e343e04855d9ff3c61de4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765200960,
      "headline": "Watch 5 Bigwigs in December After Double-Digit Returns Past Month",
      "id": 137732208,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Five market giants, CVNA, WMT, AMAT, FCX and MRK, delivered double-digit returns last month with more room to run in December.",
      "url": "https://finnhub.io/api/news?id=69a17417fb192bb42074c8db2788f230a77150ffe46e343e04855d9ff3c61de4"
    }
  },
  {
    "ts": null,
    "headline": "Saskatchewan Adds CAPVAXIVE® to Publicly Funded Adult Immunization Program",
    "summary": "Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the province of Saskatchewan has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to its publicly funded adult immunization program. This addition supports increased access to pneumococcal immunization for eligible adults in accordance with the provincial eligibility criteria.",
    "url": "https://finnhub.io/api/news?id=76c2fbec744623fb860fe363fdb1e71514d5785b347b126c0267169c1d767399",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765195200,
      "headline": "Saskatchewan Adds CAPVAXIVE® to Publicly Funded Adult Immunization Program",
      "id": 137732368,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the province of Saskatchewan has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to its publicly funded adult immunization program. This addition supports increased access to pneumococcal immunization for eligible adults in accordance with the provincial eligibility criteria.",
      "url": "https://finnhub.io/api/news?id=76c2fbec744623fb860fe363fdb1e71514d5785b347b126c0267169c1d767399"
    }
  },
  {
    "ts": null,
    "headline": "Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.",
    "summary": "Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City.",
    "url": "https://finnhub.io/api/news?id=01244a0d14798360e96b1cb747b5cdab4cd19b32a8f893ef84fbb33c2ccf8fab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765191600,
      "headline": "Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.",
      "id": 137732369,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City.",
      "url": "https://finnhub.io/api/news?id=01244a0d14798360e96b1cb747b5cdab4cd19b32a8f893ef84fbb33c2ccf8fab"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Merck: “The People Who Run This Company Are Not Idiots”",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection. He commented: “The people who run this company are not idiots. They’ve long known that Keytruda would lose patent protection, so, for years, they’ve been […]",
    "url": "https://finnhub.io/api/news?id=3bc889d131ccee96c8887f0d437aa2b68865c905177266a4c71d2b169aee8f32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765171925,
      "headline": "Jim Cramer on Merck: “The People Who Run This Company Are Not Idiots”",
      "id": 137732370,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection. He commented: “The people who run this company are not idiots. They’ve long known that Keytruda would lose patent protection, so, for years, they’ve been […]",
      "url": "https://finnhub.io/api/news?id=3bc889d131ccee96c8887f0d437aa2b68865c905177266a4c71d2b169aee8f32"
    }
  }
]